TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease

Johnson & Johnson (JNJ) reported Phase 3 data showing Tremfya achieved 28% and 27% fistula remission in Crohn's patients at Week 24, versus 10% for placebo. Subgroup analyses showed higher remission rates in specific patient groups. Tremfya is approved for Crohn's disease in the U.S. The data was presented at the American College of Gastroenterology 2026 meeting.

Johnson & Johnson (JNJ) reported three-year data from its Phase 3 GALAXI 2 and 3 studies on TREMFYA for Crohn's disease. 94% and 91% of patients achieved clinical remission with 100 mg and 200 mg doses, respectively. 52% and 61% achieved endoscopic remission. 74% remained on treatment for three years. Data was presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.

Johnson & Johnson announced Phase 3 data showing TREMFYA (guselkumab) achieved consistent combined fistula remission rates in Crohn's disease patients with perianal fistula, including difficult-to-treat subgroups. Remission rates were 28% and 27% for two dosing groups vs. 10% for placebo. Results were presented at the ACG 2026 Annual Scientific Meeting.

Johnson & Johnson's long-term study on TREMFYA for Crohn's disease shows 94% clinical remission and 61% endoscopic remission after three years. 88% of patients achieved 90-day corticosteroid-free remission. The data, from GALAXI 2 and 3 studies, demonstrate sustained outcomes with two dosing regimens. TREMFYA is the only approved dual-acting monoclonal antibody for inflammatory bowel disease.

Johnson & Johnson's drug TREMFYA showed consistent efficacy in treating Crohn's disease with perianal fistula across key patient subgroups, including those with prior biologic exposure. Phase 3 trial results showed 28% combined fistula remission rates. The drug is approved for Crohn's and other inflammatory conditions.

Johnson & Johnson (JNJ) reported that its oral psoriasis drug, ICOTYDE, maintained skin clearance through 112 weeks in a Phase 3 study, with 89% of genital psoriasis patients and 60% of scalp psoriasis patients achieving complete clearance. The study, presented at a dermatology congress, showed improved outcomes in difficult-to-manage areas, with no new safety concerns identified. JNJ aims to differentiate ICOTYDE in the psoriasis treatment market with its oral delivery.